Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management
Genetics already informs prognosis, may help guide therapy development beyond JAK2 inhibition
Source: medpagetoday.com
Aaron Gerds News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Aaron Gerds. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Aaron Gerds Today - Breaking & Trending Today
Monitoring Myelofibrosis Treatment Response: Guidelines and Considerations
Aaron Gerds, MD, MS, reviews the National Comprehensive Cancer Network (NCCN) guidelines for monitoring myelofibrosis treatment response and delves into crucial aspects like patient impressions, physical examinations, and symptoms.
Source: ajmc.com
Integrating Momelotinib: NCCN Guidelines and Drug Comparison
Aaron Gerds, MD, MS, explores the FDA approval of momelotinib and its swift integration into National Comprehensive Cancer Network (NCCN) guidelines. He reviews different JAK inhibitors based on adverse effects and treatment goals, addressing potential treatment-related anemia in myelofibrosis.
Source: ajmc.com
Prognosis and Treatment Strategies in Myelofibrosis: Risk Assessment and Therapeutic Goals
Aaron Gerds, MD, MS, explores myelofibrosis risk assessment, treatment goals, and therapeutic strategies, including JAK (Janus kinase inhibitors) inhibitors and transplant considerations.
Source: ajmc.com
Understanding Myelofibrosis: Disease Spectrum and Impact on Quality of Life
Aaron Gerds, MD, MS, compares myelofibrosis with other myeloproliferative neoplasms, explores its prevalence in the US, and reviews the diverse clinical presentations and the impact on patients’ quality of life.
Source: ajmc.com